67Cu-SAR-BBN
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 67Cu-SAR-BBN, covering 2025-08-29 to 2025-08-29. Get the full timeline:
Most recent: Clinical Trial Update: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) [Phase 1, Phase 2]